Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

16260 Ventura Blvd., Suite 140
Encino, CA 91436
Phone: 818-528-7776

August 29, 2019 by Alan Khadavi

Fasenra for Eosinophilic Esophagitis (EoE)

Fasenra (benralizumab) for Eosinophilic Esophagitis was made a reality today, when the FDA granted it Orphan Drug Designation (ODD). The Orphan Drug Act (ODA) provides for granting special status to a drug or biological product (“drug”) to treat a rare disease or condition upon request of a sponsor. This status is referred to as orphan designation (or sometimes “orphan status”).

Designating an Orphan Product: Drugs and Biological Products

Eosinophilic Esophagitis is a rare, chronic inflammatory disease that occurs when eosinophils, which a type of allergic white blood cell, accumulates in ones esophagus causing injury and inflammation.  The disease results in injury, fibrosis and dysfunction that is not easily treated.  Symptoms can range from eating difficulty, food getting stuck, acid reflux, leading to chronic pain, difficulty swallowing, poor growth, malnutrition and weight loss.  The most common symptoms of EoE include reflux that does not respond to acid blockers (Zantac) or proton pump inhibitors.

In previous posts, we have discussed EoE extensively and the various treatment options available.

Eosinophilic Esophagitis (EoE)

Risk Factors for Eosinophilic Esophagitis

Eosinophilic Esophagitis Diet

Eosinophilic Esophagitis in Southern California

Eosinophilic Esophagitis Treatment Options

Other Conditions in Eosinophilic Esophagitis

Fasenra (benralizumab) was approved initially for add-on maintenance therapy in severe eosinophilic asthma.  Fasenra is a monoclonal antibody that is injected and it binds directly to the IL-5 receptor alpha on eosinophils and it results in programmed cell death, resulting in rapid and near-complete depletion of eosinophils.

Benralizumab (Fasenra) in asthma

Besides Fasenra for Eosinophilic Esophagitis, it is currently in development for severe nasal polyps, eosinophilic granulomatosis with polyangitis, hypereosinophilic syndrome and chronic obstructive pulmonary disease (COPD).

Fasenra is currently dosed for asthma with a 30mg pre-filled syringe, that is given subcutaneously every 4 weeks for the first 3 months.  Thereafter, it is given every 8 weeks.  Earlier this year it was announced that Fasenra will have an auto-injector pen available, that patients can self administer at home.

Fasenra receives positive EU CHMP opinion for self-administration and the new Fasenra pen, a pre-filled, single-use auto-injector

 

 

 

Filed Under: biologics, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

January 16, 2021

Singulair psychiatric side effects; a large study

Singulair psychiatric side effects

January 11, 2021

Allegra during Pregnancy, is it safe?

allegra during pregnancy

December 25, 2020

Moderna Covid Vaccine and Allergy

moderna covid vaccine and allergy

December 12, 2020

Pfizer Covid Vaccine and Allergy

covid vaccine and allergy

December 3, 2020

Eohilia Budesonide Oral Suspension for Eosinophilic Esophagitis

eohilia

December 1, 2020

Indacaterol for severe asthma

indacaterol

November 3, 2020

New treatments for chronic hives

New treatments for chronic hives

October 29, 2020

Xolair for Allergic Rhinitis-A recent study

xolair for allergic rhinitis

October 26, 2020

Semen allergy an overview and treatment

semen allergy

October 21, 2020

Peanut Patch (Viaskin) for peanut allergy

viaskin peanut patch

Read More Posts...

Follow Us…

© 2021 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page